Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction

27 August 2022 (12:15 - 13:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

6 More presentations in this session

Presentation thumbnail

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials

Associate Professor M. Schmidt (Aarhus, DK)

Abstract Slides

Presentation thumbnail

Cardiovascular risk following cannabinoid treatment for patients with chronic pain

Mrs N. Nouhravesh (Durham, US)

Abstract Slides

Presentation thumbnail

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient

Mr E. Fort (Barcelona, ES)

Abstract Slides

Access the full session

Session thumbnail

Drug cardiotoxicity: what do we need to know?

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET

You may be interested in

Webinar

Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer

Congress Session

Recent perspectives in cardio-oncology

Congress Session

Cardio-oncology: when therapy leads to failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources